Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of PGD2 (prostaglandin D2) in preparation of drug for treating stomach cancer

A prostaglandin and drug technology, applied in the field of tumor treatment drugs, can solve problems affecting the expansion and differentiation of tumor stem cells

Inactive Publication Date: 2017-05-10
JIANGSU UNIV
View PDF1 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Cancer stem cells are considered to be the seed cells for tumor development and even drug resistance. Self-renewal ability is an important feature of tumor stem cells. The inhibition of tumor stem cell self-renewal ability is a hot spot in tumor treatment research. Whether PGD2 and related signal transduction affect There are still no public reports on the expansion and differentiation of tumor stem cells at home and abroad

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of PGD2 (prostaglandin D2) in preparation of drug for treating stomach cancer
  • Application of PGD2 (prostaglandin D2) in preparation of drug for treating stomach cancer
  • Application of PGD2 (prostaglandin D2) in preparation of drug for treating stomach cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] Example 1: Exogenous PGD2 inhibits the in vitro expansion and migration of gastric cancer cell lines SGC7901 and HGC-27

[0048] (1) Dilution of pure PGD2: Purchase PGD2 factor (1 mg) from Sigma, USA, add 100 μL of dimethyl sulfoxide (DMSO) reagent to dissolve, dilute to a mother solution with a concentration of 100 ng / μL, and then use blank 1640DMEM For the culture solution, dilute the mother solution at a ratio of 1:1000 to 100pg / μL nutrient solution (all the application solutions mentioned in the subsequent steps are at this concentration);

[0049] (2) The effect of exogenous PGD2 on the proliferation of tumor cells in vitro: HGC-27 and SGC-7901 cells were planted in 24-well plates with a cell density of 5000 / well, and different amounts of PGD2 application solutions were added to stimulate the cells. The final concentrations of exposure were: 50pg / mL, 500pg / mL and 5ng / mL, DMSO was used as the control. After 24h, 48h, and 72h of different concentrations of PGD2, the...

Embodiment 2

[0051] Example 2: Exogenous PGD2 inhibits gastric cancer cell self-renewal ability and related gene expression

[0052] The dilution of PGD2 pure product is with embodiment 1.

[0053] (1) Inhibitory effect of exogenous PGD2 on tumor cell sphere formation ability (self-renewal ability): first prepare stem cell serum-free medium (formulation: 20ng / mL EGF, 10ng / mL FGF, 1:50 B27 factor), HGC-27 and SGC-7901 cells were planted in 6-well plates, the culture condition was serum-free stem cell culture medium, and the cell density was 5000 / well. At the same time, different amounts of PGD2 application solution were added for stimulation, so that the final concentration of cells contacted was : 50pg / mL, 500pg / mL and 5ng / mL, DMSO was used as the control, after 7 days of culture, the number of spheres was observed under a 40-fold microscope (a sphere with a diameter greater than 70μm), and the size of the spheres was observed under a 200-fold microscope. It was shown that, compared with ...

Embodiment 3

[0057] Example 3: Knocking down the rate-limiting enzyme L-PTGDS and PGD2 receptor molecule CRTH2 synthesized by PGD2 in gastric cancer by small hairpin RNA (shRNA) proved the inhibitory effect of endogenous PGD2 on the proliferation and migration of tumor cells in vitro, and suggested that This role is accomplished through CRTH2 signaling.

[0058] The key molecules involved in Example 3 are introduced: L-PTGDS is the key enzyme for the synthesis of PGD2. In other words, the expression level of L-PTGDS affects the amount of PGD2 secreted by the cells themselves. Knocking down the expression of L-PTGDS can effectively reduce PGD2 CRTH2 is an important receptor for PGD2 binding, mainly expressed on the cell membrane, and is an important molecule for PGD2 to transmit signals into cells. Knocking down CRTH2 can block the function of PGD2 on target cells.

[0059] The specific implementation steps of Embodiment 3 of the present invention are described as follows:

[0060] (1) Con...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of PGD2 (prostaglandin D2) in preparation of a drug for treating stomach cancer and belongs to the technical field of tumor treatment drugs. Tests prove that PGD2 can effectively inhibit in-vitro expansion and migration of tumor cells and further can inhibit expression labeled by tumor stem cells of stomach cancer cells and self-renewal capability of tumor cells and also prove that the function is completed by aid of CRTH2 signals. The new function of PGD2 on inhibiting tumor stem cells characteristics by the aid of PGD2 and a new mechanism of PGD2 for controlling development of stomach cancer are disclosed firstly. Therefore, the PGD2 has great clinical significance.

Description

technical field [0001] The invention belongs to the technical field of drugs for treating tumors, and relates to the application of prostaglandin D2 (PGD2) in the preparation of drugs for treating gastric cancer. Background technique [0002] PGD2 is a kind of prostaglandin and is an important cell signaling molecule. Its synthesis is mainly through the following biological process: phospholipase A on the cell membrane is converted into arachidonic acid, which is converted into arachidonic acid in cyclooxygenase (including COX-1 Under the catalysis of COX-2), it is decomposed into an unstable intermediate product prostaglandin H2, which is then decomposed by three different enzymes: prostaglandin D synthase (PGDS), prostaglandin E synthase and prostaglandin F Synthetase converts to more stable PGD2, PGE2, PGF2. The key enzymes of the PGDS prostaglandin series include lipocalin-type PGD synthase (L-PTGDS) and hematopoietic PGD synthase (H-PTGDS); [0003] Studies have shown...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/5575A61P35/00A61P35/04
CPCA61K31/5575
Inventor 张斌别庆丽史惠许文荣钱晖吴佩佩贾浩源潘昭吉尤本帅杨伦宇
Owner JIANGSU UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com